The probable actions of sulforaphane (SFN; 1-isothiocyanate-4-methylsulphinylbutane) in CKD involve the prevention or diminution of structural injury and alterations in renal function; the reduction of proteinuria by moderating inflammation through increased mRNA expression of Nrf2, NADPH quinone oxidoreductase 1 (NQO-1), HO-1, and SOD; and decreasing OS. Here, NQO1 is linked to chronic kidney disease.